Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine and Temozolomide in Recurrent Glioblastoma
NCT06410248Phase 1Recruiting
- Sponsor
- Northwestern University
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of triapine in glioblastoma (GBM) (2 arms), sponsored by Northwestern University. Primary endpoint: Recommended Phase 2 Dose. Started Jul 2024; status: recruiting.
02
Drugs
triapine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06410248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410248.